Back to top
more

GENEDX HOLDINGS (WGS)

(Delayed Data from NSDQ)

$19.72 USD

19.72
238,124

-0.27 (-1.35%)

Updated May 23, 2024 04:00 PM ET

After-Market: $19.65 -0.07 (-0.35%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 249)

Industry: Medical Services

Better trading starts here.

Zacks News

GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Tops Revenue Estimates

GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of 51.47% and 25.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Virtu, Coinbase, General Mills in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Here's Why GENEDX HOLDINGS (WGS) Could be Great Choice for a Bottom Fisher

GENEDX HOLDINGS (WGS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over GeneDx Holdings Corp. (WGS), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for GeneDx Holdings Corp. (WGS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

PacBio (PACB) Inks Research Collaboration for Genome Sequencing

PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.

Brookdale (BKD) May 2023 Occupancy Rises: Better Days Ahead?

Brookdale (BKD) has witnessed 19 straight months of year-over-year increases in weighted average occupancy level.

Humana (HUM) Arm Reaches 250 Senior Primary Care Facilities

Humana's (HUM) CenterWell business focuses on providing a better healthcare experience through clubbing primary care, home health and pharmacy services.

Should You Retain Acadia Healthcare (ACHC) in Your Portfolio?

Acadia Healthcare's (ACHC) top line is likely to receive support from growth in specialty treatment and acute inpatient psychiatric facilities.

Encompass Health (EHC) to Build New Hospital in Concordville

The new inpatient rehabilitation unit is likely to be the 10th hospital of Encompass Health (EHC) in Pennsylvania.

HCA Healthcare (HCA) to Acquire 41 Urgent Care Centers in Texas

HCA Healthcare (HCA) expects the acquisition of urgent care centers from FastMed to close by this summer.

Here's Why Hold Strategy is Apt for Centene (CNC) Stock Now

Centene's (CNC) health benefit ratio is estimated at 87.1-87.7% for 2023, signaling better operating efficiency.

Down -27.82% in 4 Weeks, Here's Why You Should You Buy the Dip in GeneDx Holdings Corp. (WGS)

GeneDx Holdings Corp. (WGS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Elevance (ELV) to Divest Life & Disability Business to StanCorp

With the sale of the life and disability business, Elevance Health (ELV) is focusing on growing its more profitable operations.

Similar Genomics Systems (OMIC) Reports Q4 Loss, Tops Revenue Estimates

Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 21.62% and 27.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Agilon Health (AGL) Reports Q4 Loss, Tops Revenue Estimates

Agilon (AGL) delivered earnings and revenue surprises of -75% and 3.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?